Glenmark Laboratories

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company headquartered in Mumbai, India, with a presence in over 80 countries. Founded in 1977, the company has transitioned from a generics manufacturer into an innovation-driven player focusing on dermatology, respiratory, and oncology. Its innovative pipeline is primarily managed through its biotech arm, Ichnos Glenmark Innovation (IGI), which leverages the proprietary BEAT platform to develop multi-specific antibodies. Glenmark's portfolio includes a mix of branded formulations, complex generics, and specialty products like the global nasal spray Ryaltris. The company maintains a strong manufacturing and R&D infrastructure across four continents and is publicly traded on the Indian stock exchanges.